Bispecific antibodies in acute lymphoblastic leukemia therapy

References

• Paul S, Kantarjian H, Jabbour EJ. Adult acute lymphoblastic leukemia. Mayo Clin Proc. 2016;91(11):1645–1666.
   PubMed Web of Science ®Google Scholar
• Pulte D, Redaniel MT, Jansen L, et al. Recent trends in survival of adult patients with acute leukemia: overall improvements, but persistent and partly increasing disparity in survival of patients from minority groups. Haematologica. 2013;98(2):222–229.
   PubMed Web of Science ®Google Scholar
• Pui C-H, Evans WE. A 50-year journey to cure childhood acute lymphoblastic leukemia. Semin Hematol. 2013;50(3):185–196.
   PubMed Web of Science ®Google Scholar
• Hunger SP, Mullighan CG, Longo DL. Acute Lymphoblastic Leukemia in Children. N Engl J Med. 2015;373(16):1541–1552.
   PubMed Web of Science ®Google Scholar
• Trama A, Botta L, Foschi R, et al. Survival of European adolescents and young adults diagnosed with cancer in 2000–07: population-based data from EUROCARE-5. Lancet Oncol. 2016;17(7):896–906.
   PubMed Web of Science ®Google Scholar
• Carobolante F, Chiaretti S, Skert C, et al. Practical guidance for the management of acute lymphoblastic leukemia in the adolescent and young adult population. Ther Adv Hematol. 2020;11(2040620720903531).
   Web of Science ®Google Scholar
• Fielding AK, Richards SM, Chopra R, et al. Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study. Blood. 2007;109(3):944–950.
   PubMed Web of Science ®Google Scholar
• Goto H. Childhood relapsed acute lymphoblastic leukemia: biology and recent treatment progress. Pediatr Int. 2015;57(6):1059–1066.
   PubMed Web of Science ®Google Scholar
• Gokbuget N, Stanze D, Beck J, et al. Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation. Blood. 2012;120(10):2032–2041.
   PubMed Web of Science ®Google Scholar
• Bassan R, Spinelli O, Oldani E, et al. Different molecular levels of post-induction minimal residual disease may predict hematopoietic stem cell transplantation outcome in adult Philadelphia-negative acute lymphoblastic leukemia. Blood Cancer J. 2014;4:e225.
   Google Scholar
• Berry DA, Zhou S, Higley H, et al. Association of minimal residual disease with clinical outcome in pediatric and adult acute lymphoblastic leukemia: a meta-analysis. JAMA Oncol. 2017;3(7):e170580.
   PubMed Web of Science ®Google Scholar
• Bruggemann M, Gokbuget N, Kneba M. Acute lymphoblastic leukemia: monitoring minimal residual disease as a therapeutic principle. Semin Oncol. 2012;39(1):47–57.
   PubMed Web of Science ®Google Scholar
• Eckert C, Hagedorn N, Sramkova L, et al. Monitoring minimal residual disease in children with high-risk relapses of acute lymphoblastic leukemia: prognostic relevance of early and late assessment. Leukemia. 2015;29(8):1648–1655.
   PubMed Web of Science ®Google Scholar
• Gokbuget N, Kneba M, Raff T, et al. Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies. Blood. 2012;120(9):1868–1876.
   PubMed Web of Science ®Google Scholar
• van Dongen JJ, van der Velden VH, Bruggemann M, et al. Minimal residual disease diagnostics in acute lymphoblastic leukemia: need for sensitive, fast, and standardized technologies. Blood. 2015;125(26):3996–4009.
   PubMed Web of Science ®Google Scholar
• Mohseni M, Uludag H, Brandwein JM. Advances in biology of acute lymphoblastic leukemia (ALL) and therapeutic implications. Am J Blood Res. 2018;8(4):29–56.
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Stein A, Gokbuget N, et al., Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med. 376(9): 836–847. 2017. .
   PubMed Web of Science ®Google Scholar
• Papadantonakis N, Advani AS. Recent advances and novel treatment paradigms in acute lymphocytic leukemia. Ther Adv Hematol. 2016;7(5):252–269.
   PubMed Web of Science ®Google Scholar
• Rambaldi A, Ribera J-M, Kantarjian HM, et al. Blinatumomab compared with standard of care for the treatment of adult patients with relapsed/refractory Philadelphia chromosome–positive B-precursor acute lymphoblastic leukemia. Cancer. 2020;126(2):304–310.
   PubMed Web of Science ®Google Scholar
• Greinix HT. Role of CAR-T cell therapy in B-cell acute lymphoblastic leukemia. memo. Memo - Magazine of European Medical Oncology. 2020;13(1):36–42.
   Google Scholar
• Nagorsen D, Kufer P, Baeuerle PA, et al. Blinatumomab: a historical perspective. Pharmacol Ther. 2012;136(3):334–342.
   PubMed Web of Science ®Google Scholar
• Löffler A, Kufer P, Lutterbüse R, et al. A recombinant bispecific single-chain antibody, CD19 × CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes. Blood. 2000;95(6):2098–2103.
   PubMed Web of Science ®Google Scholar
• Dreier T, Lorenczewski G, Brandl C, et al. Extremely potent, rapid and costimulation-independent cytotoxic T-cell response against lymphoma cells catalyzed by a single-chain bispecific antibody. Int J Cancer. 2002;100(6):690–697.
   PubMed Web of Science ®Google Scholar
• Hoffmann P, Hofmeister R, Brischwein K, et al. Serial killing of tumor cells by cytotoxic T cells redirected with a CD19-/CD3-bispecific single-chain antibody construct. Int J Cancer. 2005;115(1):98–104.
   PubMed Web of Science ®Google Scholar
• Loffler A, Gruen M, Wuchter C, et al. Efficient elimination of chronic lymphocytic leukaemia B cells by autologous T cells with a bispecific anti-CD19/anti-CD3 single-chain antibody construct. Leukemia. 2003;17(5):900–909.
   PubMed Web of Science ®Google Scholar
• Zimmerman Z, Maniar T, Nagorsen D. Unleashing the clinical power of T cells: CD19/CD3 bi-specific T cell engager (BiTE(R)) antibody construct blinatumomab as a potential therapy. Int Immunol. 2015;27(1):31–37.
   PubMed Web of Science ®Google Scholar
• Fooksman DR, Vardhana S, Vasiliver-Shamis G, et al. Functional anatomy of T cell activation and synapse formation. Annu Rev Immunol. 2010;28(1):79–105.
   PubMedGoogle Scholar
• Offner S, Hofmeister R, Romaniuk A, et al. Induction of regular cytolytic T cell synapses by bispecific single-chain antibody constructs on MHC class I-negative tumor cells. Mol Immunol. 2006;43(6):763–771.
   PubMed Web of Science ®Google Scholar
• Dreier T, Baeuerle PA, Fichtner I, et al. T cell costimulus-independent and very efficacious inhibition of tumor growth in mice bearing subcutaneous or leukemic human B cell lymphoma xenografts by a CD19-/CD3- bispecific single-chain antibody construct. J Immunol. 2003;170(8):4397–4402.
   PubMed Web of Science ®Google Scholar
• Klinger M, Brandl C, Zugmaier G, et al. Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell–engaging CD19/CD3-bispecific BiTE antibody blinatumomab. Blood. 2012;119(26):6226–6233.
   PubMed Web of Science ®Google Scholar
• Klinger M, Zugmaier G, Nagele V, et al. Adhesion of T cells to endothelial cells facilitates blinatumomab-associated neurologic adverse events. Cancer Res. 2020;80(1):91–101.
   PubMed Web of Science ®Google Scholar
• Gruen M, Bommert K, Bargou RC. T-cell-mediated lysis of B cells induced by a CD19xCD3 bispecific single-chain antibody is perforin dependent and death receptor independent. Cancer Immunol Immunother. 2004;53(7):625–632.
   PubMed Web of Science ®Google Scholar
• Mack M, Riethmuller G, Kufer P. A small bispecific antibody construct expressed as a functional single-chain molecule with high tumor cell cytotoxicity. Proc Natl Acad Sci U S A. 1995;92(15):7021–7025.
   PubMed Web of Science ®Google Scholar
• Kischel RHS, Baeuerle P, Kufer P Effector memory T cells make a major contribution to redirected target cell lysis by T cell-engaging BiTE antibody MT110. [Abstract]. AACR Annual Meeting, Apr 18-22; Denver, CO (2009).
   Google Scholar
• Hijazi Y, Klinger M, Kratzer A, et al. Pharmacokinetic and pharmacodynamic relationship of blinatumomab in patients with non-hodgkin lymphoma. Curr Clin Pharmacol. 2018;13(1):55–64.
   PubMed Web of Science ®Google Scholar
• Viardot A, Goebeler M-E, Hess G, et al. Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed/refractory diffuse large B-cell lymphoma. Blood. 2016;127(11):1410–1416.
   PubMed Web of Science ®Google Scholar
• Zhu M, Wu B, Brandl C, et al. Blinatumomab, a bispecific T-cell Engager (BiTE®) for CD-19 targeted cancer immunotherapy: clinical pharmacology and its implications. Clin Pharmacokinet. 2016;55(10):1271–1288.
   PubMed Web of Science ®Google Scholar
• Klinger M, Benjamin J, Kischel R, et al. Harnessing T cells to fight cancer with BiTE ® antibody constructs - past developments and future directions. Immunol Rev. 2016;270(1):193–208. .
   PubMed Web of Science ®Google Scholar
• Goekbuget N, Dombret H, Bonifacio M, et al., BLAST: a confirmatory, single-arm, phase 2 study of Blinatumomab, a bispecific T-cell engager (BiTE®) antibody construct, in patients with minimal residual disease B-precursor acute lymphoblastic leukemia (ALL). Blood. 124(21): 379. 2014. .
   Web of Science ®Google Scholar
• Martinelli G, Boissel N, Chevallier P, et al., Complete hematologic and molecular response in adult patients with relapsed/refractory philadelphia Chromosome–positive B-Precursor Acute lymphoblastic leukemia following treatment with Blinatumomab: results from a phase II, single-arm, multicenter study. J Clin Oncol. 35(16): 1795–1802. 2017.
   PubMed Web of Science ®Google Scholar
• Topp MS, Gokbuget N, Stein AS, et al. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Oncol. 2015;16(1):57–66.
   PubMed Web of Science ®Google Scholar
• Topp MS, Gokbuget N, Zugmaier G, et al. Phase II Trial of the Anti-CD19 Bispecific T Cell–engager Blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-Precursor Acute lymphoblastic leukemia. J Clin Oncol. 2014;32(36):4134–4140.
   PubMed Web of Science ®Google Scholar
• von Stackelberg A, Locatelli F, Zugmaier G, et al., Phase I/phase II study of Blinatumomab in pediatric patients with relapsed/refractory acute lymphoblastic leukemia. J Clin Oncol. 34(36): 4381–4389. 2016. .
   PubMed Web of Science ®Google Scholar
• Topp MS, Kufer P, Gokbuget N, et al. Targeted therapy with the T-Cell–engaging antibody Blinatumomab of chemotherapy-refractory minimal residual disease in B-Lineage Acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J Clin Oncol. 2011;29(18):2493–2498.
   PubMed Web of Science ®Google Scholar
• Bargou R, Leo E, Zugmaier G, et al. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science. 2008;321(5891):974–977.
   PubMed Web of Science ®Google Scholar
• Goebeler M-E, Knop S, Viardot A, et al. Bispecific T-cell engager (BiTE) antibody construct Blinatumomab for the treatment of patients with relapsed/refractory non-Hodgkin lymphoma: final results from a phase I study. J Clin Oncol. 2016;34(10):1104–1111.
   PubMed Web of Science ®Google Scholar
• FDA. Clinical pharmacology and biopharmaceutics review(s), BLA 125557. 2014 [cited 2020 May 29]. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/125557Orig1s000ClinPharmRedt.pdf
   Google Scholar
• Zhu M, Kratzer A, Johnson J, et al. Blinatumomab Pharmacodynamics and Exposure-Response Relationships in Relapsed/Refractory Acute Lymphoblastic Leukemia. J Clin Pharmacol. 2018;58(2):168–179.
   PubMed Web of Science ®Google Scholar
• Clements JD, Zhu M, Kuchimanchi M, et al. Population pharmacokinetics of blinatumomab in pediatric and adult patients with hematological malignancies. Clin Pharmacokinet. 2020;59(4):463–474.
   PubMed Web of Science ®Google Scholar
• Robinson AC, Marini BL, Pettit KM, et al. Successful use of blinatumomab in a patient with acute lymphoblastic leukemia and severe hepatic dysfunction. J Oncol Pharm Pract. 2020;26(1):200–205.
   PubMed Web of Science ®Google Scholar
• Stein AS, Larson RA, Schuh AC, et al. Exposure-adjusted adverse events comparing blinatumomab with chemotherapy in advanced acute lymphoblastic leukemia. Blood Advances. 2018;2(13):1522–1531.
   PubMed Web of Science ®Google Scholar
• Stein AS, Schiller G, Benjamin R, et al. Neurologic adverse events in patients with relapsed/refractory acute lymphoblastic leukemia treated with blinatumomab: management and mitigating factors. Ann Hematol. 2019;98(1):159–167.
   PubMed Web of Science ®Google Scholar
• Shimabukuro-Vornhagen A, Godel P, Subklewe M, et al. Cytokine release syndrome. J Immunother Cancer. 2018;6(1):56.
   PubMed Web of Science ®Google Scholar
• Brandl C, Haas C, d’Argouges S, et al. The effect of dexamethasone on polyclonal T cell activation and redirected target cell lysis as induced by a CD19/CD3-bispecific single-chain antibody construct. Cancer Immunol Immunother. 2007;56(10):1551–1563.
   PubMed Web of Science ®Google Scholar
• Walz A, Andratschke M, Wollenberg B, et al. Prednisolone reduces TNF-alpha release by PBMCs activated with a trifunctional bispecific antibody but not their anti-tumor activity. Anticancer Res. 2005;25(6B):4239–4243.
   Web of Science ®Google Scholar
• Aldoss I, Song J, Stiller T, et al. Correlates of resistance and relapse during blinatumomab therapy for relapsed/refractory acute lymphoblastic leukemia. Am J Hematol. 2017;92(9):858–865.
   PubMed Web of Science ®Google Scholar
• Barrett DM, Singh N, Hofmann TJ, et al. Interleukin 6 is not made by chimeric antigen receptor T cells and does not impact their function. [Abstract]. Blood. 2016;128(22):654.
   Google Scholar
• Davila ML, Riviere I, Wang X, et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med. 2014;6(224):224ra25.
   PubMed Web of Science ®Google Scholar
• Grupp SA, Kalos M, Barrett D, et al. Chimeric antigen receptor–modified T cells for Acute lymphoid leukemia. N Engl J Med. 2013;368(16):1509–1518.
   PubMed Web of Science ®Google Scholar
• Jen EY, Xu Q, Schetter A, et al. FDA approval: blinatumomab for patients with B-cell precursor acute lymphoblastic leukemia in morphologic remission with minimal residual disease. Clin Cancer Res. 2019;25(2):473–477.
   PubMed Web of Science ®Google Scholar
• FDA. Briefing document for oncologic drugs advisory committee meeting, BLA 125557 S-013. 2018 [cited 2020 Apr 29]. https://www.fda.gov/media/111622/download;https://www.fda.gov/media/111628/download
   Google Scholar
• Kebenko M, Goebeler M-E, Wolf M, et al. A multicenter phase 1 study of solitomab (MT110, AMG 110), a bispecific EpCAM/CD3 T-cell engager (BiTE®) antibody construct, in patients with refractory solid tumors. Oncoimmunology. 2018;7(8):e1450710.
   PubMed Web of Science ®Google Scholar
• Ravandi F, Stein AS, Kantarjian HM, et al. A phase 1 first-in-human study of AMG 330, an Anti-CD33 bispecific T-cell engager (BiTE®) antibody construct, in relapsed/refractory acute myeloid leukemia (R/R AML). [Abstract]. Blood. 2018;132(Supplement 1):25.
   Google Scholar
• Schuster SJ, Bartlett NL, Assouline S, et al. Mosunetuzumab induces complete remissions in poor prognosis non-Hodgkin lymphoma patients, including those who are resistant to or relapsing after chimeric antigen receptor T-cell (CAR-T) therapies, and is active in treatment through multiple lines. [Abstract]. Blood. 2019;134(Supplement_1):6.
   PubMed Web of Science ®Google Scholar
• Kranick S, Phan G, Kochenderfer J, et al. Aphasia as a complication of CD19-targeted chimeric antigen receptor immunotherapy. [Abstract]. Neurology. 2014;82(10 Supplement):S52.006.
   Google Scholar
• Santomasso BD, Park JH, Salloum D, et al. Clinical and biological correlates of neurotoxicity associated with CAR T-cell therapy in patients with B-cell Acute lymphoblastic leukemia. Cancer Discov. 2018;8(8):958–971.
   PubMed Web of Science ®Google Scholar
• Bargou RC, Zugmaier G, Bonifacio M, et al. Health-related quality of life in adults with B-cell precursor acute lymphoblastic leukemia and minimal residual disease treated with Blinatumomab. [Abstract]. Blood. 2018;132(Supplement 1):1377.
   Google Scholar
• Stein A, Franklin JL, Chia VM, et al. Benefit–risk assessment of Blinatumomab in the treatment of relapsed/refractory B-cell precursor Acute LYMPHOBLASTIC LEUKEMia. Drug Saf. 2019;42(5):587–601.
   PubMed Web of Science ®Google Scholar
• Siddiqui O. Statistical methods to analyze adverse events data of randomized clinical trials. Journal of Biopharmaceutical Statistics. 2009;19(5):889–899.
   PubMed Web of Science ®Google Scholar
• Bassan R, Bruggemann M, Radcliffe H-S, et al. A systematic literature review and meta-analysis of minimal residual disease as a prognostic indicator in adult B-cell acute lymphoblastic leukemia. Haematologica. 2019;104(10):2028–2039.
   PubMed Web of Science ®Google Scholar
• Giebel S, Labopin M, Socie G, et al. Improving results of allogeneic hematopoietic cell transplantation for adults with acute lymphoblastic leukemia in first complete remission: an analysis from the Acute leukemia working party of the European society for blood and marrow transplantation. Haematologica. 2017;102(1):139–149.
   PubMed Web of Science ®Google Scholar
• Bader P, Hancock J, Kreyenberg H, et al. Minimal residual disease (MRD) status prior to allogeneic stem cell transplantation is a powerful predictor for post-transplant outcome in children with ALL. Leukemia. 2002;16(9):1668–1672.
   PubMed Web of Science ®Google Scholar
• Bader P, Kreyenberg H, Henze GHR, et al. Prognostic value of minimal residual disease quantification before allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia: the ALL-REZ BFM study group. J Clin Oncol. 2009;27(3):377–384.
   PubMed Web of Science ®Google Scholar
• Zhao X-S, Liu Y-R, Xu L-P, et al. Minimal residual disease status determined by multiparametric flow cytometry pretransplantation predicts the outcome of patients with ALL receiving unmanipulated haploidentical allografts. Am J Hematol. 2019;94(5):512–521.
   PubMed Web of Science ®Google Scholar
• Gokbuget N, Zugmaier G, Klinger M, et al. Long-term relapse-free survival in a phase 2 study of blinatumomab for the treatment of patients with minimal residual disease in B-lineage acute lymphoblastic leukemia. Haematologica. 2017;102(4):e132–e135.
   PubMed Web of Science ®Google Scholar
• Topp MS, Gokbuget N, Zugmaier G, et al. Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL. Blood. 2012;120(26):5185–5187.
   PubMed Web of Science ®Google Scholar
• Gokbuget N, Dombret H, Bonifacio M, et al. Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia. Blood. 2018;131(14):1522–1531.
   PubMed Web of Science ®Google Scholar
• Goekbuget N, Dombret H, Zugmaier G, et al. S1619 Blinatumomab for minimal residual disease (MRD) in adults with B Cell precursor acute lymphoblastic leukemia (BCPALL): median overall survival (OS) not reached at 5 years for complete mrd responders. [Abstract]. HemaSphere. 2019;3(S1):747.
   Google Scholar
• Locatelli F, Zugmaier G, Bader P, et al. Blinatumomab in pediatric patients with relapsed/refractory B-cell precursor and molecularly resistant Acute lymphoblastic leukemia (R/R ALL): updated analysis of 110 patients treated in an expanded access study (RIALTO). [Abstract]. Blood. 2019;134(Supplement_1):1294.
   Google Scholar
• Gokbuget N, Kantarjian HM, Bruggemann M, et al. Molecular response with blinatumomab in relapsed/refractory B-cell precursor acute lymphoblastic leukemia. Blood Advances. 2019;3(20):3033–3037.
   PubMed Web of Science ®Google Scholar
• Kiyoi H, Morris JD, Oh I, et al. Phase 1b/2 study of blinatumomab in Japanese adults with relapsed/refractory acute lymphoblastic leukemia. Cancer Science. 2020;111(4):1314–1323.
   PubMed Web of Science ®Google Scholar
• Jabbour EJ, Gokbuget N, Kantarjian HM, et al. Transplantation in adults with relapsed/refractory acute lymphoblastic leukemia who are treated with blinatumomab from a phase 3 study. Cancer. 2019;125(23):4181–4192.
   PubMed Web of Science ®Google Scholar
• Brown P, Zugmaier G, Gore L, et al. Day 15 bone marrow minimal residual disease predicts response to blinatumomab in relapsed/refractory paediatric B-ALL. Br J Haematol. 2020;188(4):e36–e9.
   PubMed Web of Science ®Google Scholar
• Gore L, Locatelli F, Zugmaier G, et al. Survival after blinatumomab treatment in pediatric patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia. Blood Cancer Journal. 2018;8(9):80.
   PubMedGoogle Scholar
• Brown PA, Ji L, Xu X, et al. A randomized phase 3 trial of blinatumomab vs. chemotherapy as post-reinduction therapy in high and intermediate risk (HR/IR) first relapse of B-Acute lymphoblastic leukemia (B-ALL) in Children and adolescents/young adults (AYAs) demonstrates superior efficacy and tolerability of Blinatumomab: a report from Children’s oncology group study AALL1331. [Abstract]. Blood. 2019;134(Supplement_2):LBA–1.
   Google Scholar
• Ravandi F. Current management of Philadelphia chromosome positive all and the role of stem cell transplantation. Hematology Am Soc Hematol Educ Program. 2017; 1:22–27.
   Google Scholar
• Soverini S, Bassan R, Lion T. Treatment and monitoring of Philadelphia chromosome-positive leukemia patients: recent advances and remaining challenges. J Hematol Oncol. 2019;12(1):39.
   PubMedGoogle Scholar
• Mian AA, Schull M, Zhao Z, et al. The gatekeeper mutation T315I confers resistance against small molecules by increasing or restoring the ABL-kinase activity accompanied by aberrant transphosphorylation of endogenous BCR, even in loss-of-function mutants of BCR/ABL. Leukemia. 2009;23(9):1614–1621.
   PubMed Web of Science ®Google Scholar
• Assi R, Kantarjian H, Short NJ, et al. Safety and efficacy of blinatumomab in combination with a tyrosine kinase inhibitor for the treatment of relapsed philadelphia chromosome-positive leukemia. Clin Lymphoma Myeloma Leuk. 2017;17(12):897–901.
   PubMed Web of Science ®Google Scholar
• Couturier M-A, Thomas X, Raffoux E, et al. PS946 BLINATUMOMAB + PONATINIB for relapsed ph1-positive Acute lymphoblastic leukemia: the French experience. [Abstract]. HemaSphere. 2019;3(S1):426–427.
   Google Scholar
• El Chaer F, Holtzman NG, Sausville EA, et al. Relapsed philadelphia chromosome-positive pre-B-ALL after CD19-directed CAR-T cell therapy successfully treated with combination of blinatumomab and ponatinib. Acta Haematol. 2019;141(2):107–110.
   PubMed Web of Science ®Google Scholar
• King AC, Pappacena JJ, Tallman MS, et al. Blinatumomab administered concurrently with oral tyrosine kinase inhibitor therapy is a well-tolerated consolidation strategy and eradicates measurable residual disease in adults with Philadelphia chromosome positive acute lymphoblastic leukemia. Leuk Res. 2019;79:27–33.
   PubMed Web of Science ®Google Scholar
• Sokolov AN, Parovichnikova EN, Troitskaya VV, et al. Blinatumomab + Tyrosine Kinase Inhibitors with no chemotherapy in BCR-ABL-positive or IKZF1-deleted or FLT3-ITD-positive relapsed/refractory acute lymphoblastic leukemia patients: high molecular remission rate and toxicity profile. [Abstract]. Blood. 2017;130(Supplement1):3884.
   Google Scholar
• McCloskey JK, Gagnon J, McCabe T, et al. Blinatumomab in combination with tyrosine kinase inhibitors safely and effectively induces rapid, deep, and durable molecular responses in relapsed and refractory philadelphia positive Acute leukemias. [Abstract]. Blood. 2019;134(Supplement_1):3812.
   Google Scholar
• Braig F, Brandt A, Goebeler M, et al. Resistance to anti-CD19/CD3 BiTE in acute lymphoblastic leukemia may be mediated by disrupted CD19 membrane trafficking. Blood. 2017;129(1):100–104.
   PubMed Web of Science ®Google Scholar
• Mejstrikova E, Hrusak O, Borowitz MJ, et al. CD19-negative relapse of pediatric B-cell precursor acute lymphoblastic leukemia following blinatumomab treatment. Blood Cancer Journal. 2017;7(12):659.
   PubMed Web of Science ®Google Scholar
• Aldoss I, Forman SJ. How I treat adults with advanced acute lymphoblastic leukemia eligible for CD19-targeted immunotherapy. Blood. 2020;135(11):804–813.
   PubMed Web of Science ®Google Scholar
• Jabbour E, Dull J, Yilmaz M, et al. Outcome of patients with relapsed/refractory acute lymphoblastic leukemia after blinatumomab failure: no change in the level of CD19 expression. Am J Hematol. 2018;93(3):371–374.
   PubMed Web of Science ®Google Scholar
• Ruella M, Maus MV. Catch me if you can: leukemia escape after CD19-directed T cell immunotherapies. Comput Struct Biotechnol J. 2016;14:357–362.
   PubMed Web of Science ®Google Scholar
• Orlando EJ, Han X, Tribouley C, et al. Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia. Nat Med. 2018;24(10):1504–1506.
   PubMed Web of Science ®Google Scholar
• Sotillo E, Barrett DM, Black KL, et al. Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy. Cancer Discov. 2015;5(12):1282–1295.
   PubMed Web of Science ®Google Scholar
• He RR, Nayer Z, Hogan M, et al. Immunotherapy- (Blinatumomab-) related lineage switch of KMT2A/AFF1 rearranged B-lymphoblastic leukemia into Acute myeloid leukemia/myeloid sarcoma and subsequently into B/myeloid mixed phenotype Acute leukemia. Case Rep Hematol. 2019;7394619:2019.
   Google Scholar
• Jacoby E. Relapse and resistance to CAR-T cells and Blinatumomab in hematologic malignancies. Clin Hematol Int. 2019;1(2):79–84.
   PubMedGoogle Scholar
• Rossi JG, Bernasconi AR, Alonso CN, et al. Lineage switch in childhood acute leukemia: an unusual event with poor outcome. Am J Hematol. 2012;87(9):890–897.
   PubMed Web of Science ®Google Scholar
• Gardner R, Wu D, Cherian S, et al. Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy. Blood. 2016;127(20):2406–2410.
   PubMed Web of Science ®Google Scholar
• Rayes A, McMasters RL, O’Brien MM. Lineage switch in MLL-rearranged infant leukemia following CD19-directed therapy. Pediatr Blood Cancer. 2016;63(6):1113–1115.
   PubMed Web of Science ®Google Scholar
• Wolfl M, Rasche M, Eyrich M, et al. Spontaneous reversion of a lineage switch following an initial blinatumomab-induced ALL-to-AML switch in MLL-rearranged infant ALL. Blood Adv. 2018;2(12):1382–1385.
   PubMed Web of Science ®Google Scholar
• Balducci E, Nivaggioni V, Boudjarane J, et al. Lineage switch from B acute lymphoblastic leukemia to acute monocytic leukemia with persistent t(4;11)(q21;q23) and cytogenetic evolution under CD19-targeted therapy. Ann Hematol. 2017;96(9):1579–1581.
   PubMed Web of Science ®Google Scholar
• Duffner U, Abdel-Mageed A, Younge J, et al. The possible perils of targeted therapy. Leukemia. 2016;30(7):1619–1621.
   PubMed Web of Science ®Google Scholar
• Nagel I, Bartels M, Duell J, et al. Hematopoietic stem cell involvement in BCR-ABL1-positive ALL as a potential mechanism of resistance to blinatumomab therapy. Blood. 2017;130(18):2027–2031.
   PubMed Web of Science ®Google Scholar
• Cohen A, Petsche D, Grunberger T, et al. Interleukin 6 induces myeloid differentiation of a human biphenotypic leukemic cell line. Leuk Res. 1992;16(8):751–760.
   PubMed Web of Science ®Google Scholar
• Wei J, Wunderlich M, Fox C, et al. Microenvironment determines lineage fate in a human model of MLL-AF9 leukemia. Cancer Cell. 2008;13(6):483–495.
   PubMed Web of Science ®Google Scholar
• Oberley MJ, Gaynon PS, Bhojwani D, et al. Myeloid lineage switch following chimeric antigen receptor T-cell therapy in a patient with TCF3-ZNF384 fusion-positive B-lymphoblastic leukemia. Pediatr Blood Cancer. 2018;65(9):e27265.
   PubMed Web of Science ®Google Scholar
• Josefowicz SZ, Lu LF, Rudensky AY. Regulatory T cells: mechanisms of differentiation and function. Annu Rev Immunol. 2012;30:531–564.
   PubMedGoogle Scholar
• Duell J, Dittrich M, Bedke T, et al. Frequency of regulatory T cells determines the outcome of the T-cell-engaging antibody blinatumomab in patients with B-precursor ALL. Leukemia. 2017;31(10):2181–2190. .
   PubMed Web of Science ®Google Scholar
• Knecht H, Kotrova M, Reigl T, et al. T-cell receptor. Repertoire characteristics in relapsed/refractory B-cell precursor Acute lymphoblastic leukemia on Blinatumomab treatment. [Abstract]. Haematologica. 2017;102:329–330.
   Google Scholar
• Zugmaier G, Gokbuget N, Klinger M, et al. Long-term survival and T-cell kinetics in relapsed/refractory all patients who achieved MRD response after blinatumomab treatment. Blood. 2015;126(24):2578–2584.
   PubMed Web of Science ®Google Scholar
• Bücklein V, Scheurer M, Brauchle B, et al. Predictors of efficacy for Blinatumomab in BCP-ALL patients: non-responders show impaired CD19-BiTE®-mediated cytotoxicity in vitro. [Abstract]. Blood. 2019;134(Supplement_1):2632.
   Google Scholar
• Dufner V, Sayehli CM, Chatterjee M, et al. Long-term outcome of patients with relapsed/refractory B-cell non-Hodgkin lymphoma treated with blinatumomab. Blood Adv. 2019;3(16):2491–2498.
   PubMed Web of Science ®Google Scholar
• Al Malki MMAI, Song J, Pullarkat V. CD19-positive extramedullary relapse of Acute lymphoblastic leukemia after Blinatumomab therapy. Austin Med Sci. 2016;1(1):1002.
   Google Scholar
• Demosthenous C, Lalayanni C, Iskas M, et al. Extramedullary relapse and discordant CD19 expression between bone marrow and extramedullary sites in relapsed acute lymphoblastic leukemia after blinatumomab treatment. Curr Probl Cancer. 2019;43(3):222–227.
   PubMed Web of Science ®Google Scholar
• Velasquez MP, Szoor A, Vaidya A, et al. CD28 and 41BB costimulation enhances the effector function of CD19-specific engager T cells. Cancer Immunol Res. 2017;5(10):860–870.
   PubMed Web of Science ®Google Scholar
• Feucht J, Kayser S, Gorodezki D, et al. T-cell responses against CD19+ pediatric acute lymphoblastic leukemia mediated by bispecific T-cell engager (BiTE) are regulated contrarily by PD-L1 and CD80/CD86 on leukemic blasts. Oncotarget. 2016;7(47):76902–76919.
   PubMed Web of Science ®Google Scholar
• Laszlo GS, Gudgeon CJ, Harrington KH, et al. T-cell ligands modulate the cytolytic activity of the CD33/CD3 BiTE antibody construct, AMG 330. Blood Cancer J. 2015;5:e340.
   PubMed Web of Science ®Google Scholar
• Balaji KN, Schaschke N, Machleidt W, et al. Surface cathepsin B protects cytotoxic lymphocytes from self-destruction after degranulation. J Exp Med. 2002;196(4):493–503.
   PubMed Web of Science ®Google Scholar
• Katz JB, Muller AJ, Prendergast GC. Indoleamine 2,3-dioxygenase in T-cell tolerance and tumoral immune escape. Immunol Rev. 2008;222:206–221.
   PubMed Web of Science ®Google Scholar
• Lehmann C, Zeis M, Schmitz N, et al. Impaired binding of perforin on the surface of tumor cells is a cause of target cell resistance against cytotoxic effector cells. Blood. 2000;96(2):594–600.
   PubMed Web of Science ®Google Scholar
• Medema JP, de Jong J, Peltenburg LT, et al. Blockade of the granzyme B/perforin pathway through overexpression of the serine protease inhibitor PI-9/SPI-6 constitutes a mechanism for immune escape by tumors. Proc Natl Acad Sci U S A. 2001;98(20):11515–11520.
   PubMed Web of Science ®Google Scholar
• Sutton VR, Vaux DL, Trapani JA. Bcl-2 prevents apoptosis induced by perforin and granzyme B, but not that mediated by whole cytotoxic lymphocytes. J Immunol. 1997;158(12):5783–5790.
   PubMed Web of Science ®Google Scholar
• Yang L, Pang Y, Moses HL. TGF-beta and immune cells: an important regulatory axis in the tumor microenvironment and progression. Trends Immunol. 2010;31(6):220–227.
   PubMed Web of Science ®Google Scholar
• Richard-Carpentier G, Kantarjian HM, Short NJ, et al. Updated Results from the Phase II Study of Hyper-CVAD in Sequential Combination with Blinatumomab in Newly Diagnosed Adults with B-Cell Acute Lymphoblastic Leukemia (B-ALL). [Abstract]. Blood. 2019;134(Supplement_1):3807.
   Google Scholar
• Jabbour EJ, Sasaki K, Ravandi F, et al. Inotuzumab ozogamicin in combination with low-intensity chemotherapy (mini-HCVD) with or without blinatumomab versus standard intensive chemotherapy (HCVAD) as frontline therapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysis. Cancer. 2019;125(15):2579–2586.
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Ravandi F, Short NJ, et al. Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study. Lancet Oncol. 2018;19(2):240–248.
   PubMed Web of Science ®Google Scholar
• Chiaretti S, Bassan R, Vitale A, et al. Dasatinib-Blinatumomab combination for the front-line treatment of adult Ph+ all patients. Updated results of the Gimema LAL2116 D-Alba trial. [Abstract]. Blood. 2019;134(Supplement_1):740.
   Google Scholar
• Dombret H, Topp MS, Schuh AC, et al. Blinatumomab versus chemotherapy in first salvage or in later salvage for B-cell precursor acute lymphoblastic leukemia. Leuk Lymphoma. 2019;60(9):2214–2222.
   PubMed Web of Science ®Google Scholar
• Kebriaei P, Banerjee PP, Ganesh C, et al. Blinatumomab is well tolerated maintenance therapy following allogeneic hematopoietic cell transplantation for Acute lymphoblastic leukemia. [Abstract]. Blood. 2019;134(Supplement_1):1298.
   PubMedGoogle Scholar
• Kobold S, Pantelyushin S, Rataj F, et al. Rationale for combining bispecific T cell activating antibodies with checkpoint blockade for cancer therapy. Front Oncol. 2018;8:285.
   PubMedGoogle Scholar
• Schwartz M, Damon LE, Jeyakumar D, et al. Blinatumomab in combination with Pembrolizumab is safe for adults with relapsed or refractory B-lineage Acute lymphoblastic leukemia: university of California hematologic malignancies consortium study 1504. [Abstract]. Blood. 2019;134(Supplement_1):3880.
   Google Scholar
• Webster J, Luskin MR, Prince GT, et al. Blinatumomab in combination with immune checkpoint inhibitors of PD-1 and CTLA-4 in adult patients with relapsed/refractory (R/R) CD19 positive B-cell Acute lymphoblastic leukemia (ALL): preliminary results of a phase i study. [Abstract]. Blood. 2018;132(Supplement1):557.
   PubMedGoogle Scholar
• Leconet W, Liu H, Guo M, et al. Anti-PSMA/CD3 bispecific antibody delivery and antitumor activity using a polymeric depot formulation. Mol Cancer Ther. 2018;17(9):1927–1940.
   PubMed Web of Science ®Google Scholar
• Nisonoff A, Rivers MM. Recombination of a mixture of univalent antibody fragments of different specificity. Arch Biochem Biophys. 1961;93:460–462.
   PubMedGoogle Scholar
• Staerz UD, Bevan MJ. Cytotoxic T lymphocyte-mediated lysis via the Fc receptor of target cells. Eur J Immunol. 1985;15(12):1172–1177.
   PubMed Web of Science ®Google Scholar
• Staerz UD, Kanagawa O, Bevan MJ. Hybrid antibodies can target sites for attack by T cells. Nature. 1985;314(6012):628–631.
   PubMed Web of Science ®Google Scholar
• Brinkmann U, Kontermann RE. The making of bispecific antibodies. MAbs. 2017;9(2):182–212.
   PubMed Web of Science ®Google Scholar
• Seimetz D. Novel monoclonal antibodies for cancer treatment: the trifunctional antibody Catumaxomab (Removab®). J Cancer. 2011;2:309–316.
   PubMed Web of Science ®Google Scholar
• Liu H, Saxena A, Sidhu SS, et al. Fc engineering for developing therapeutic bispecific antibodies and Novel scaffolds. Front Immunol. 2017;8:38. DOI:10.3389/fimmu.2017.00038
   Google Scholar
• Chu SY, Lee S-H, Rashid R, et al. Immunotherapy with long-lived Anti-CD20 × Anti-CD3 bispecific antibodies stimulates potent T Cell-mediated killing of human B cell lines and of circulating and lymphoid B cells in Monkeys: a potential therapy for B cell lymphomas and leukemias. [Abstract]. Blood. 2014;124(21):3111.
   Web of Science ®Google Scholar
• Ellerman D. Bispecific T-cell engagers: towards understanding variables influencing the in vitro potency and tumor selectivity and their modulation to enhance their efficacy and safety. Methods. 2019;154:102–117.
   PubMedGoogle Scholar
• Foster LH, Lum LG. Treatment of hematological malignancies with T cell redirected bispecific antibodies: current status and future needs. Expert Opin Biol Ther. 2019;19(7):707–720.
   PubMed Web of Science ®Google Scholar
• Klein C, Schaefer W, Regula JT, et al. Engineering therapeutic bispecific antibodies using CrossMab technology. Methods. 2019;154:21–31.
   PubMedGoogle Scholar
• Lejeune M, Kose MC, Duray E, et al. Bispecific, T-cell-recruiting antibodies in B-cell malignancies. Front Immunol. 2020;11:762. DOI:10.3389/fimmu.2020.00762
   PubMedGoogle Scholar
• Lorenczewski G, Friedrich M, Kischel R, et al. Generation of a half-life extended Anti-CD19 BiTE® antibody construct compatible with once-weekly dosing for treatment of CD19-positive malignancies. [Abstract]. Blood. 2017;130(Supplement1):2815.
   Google Scholar
• Mayer K, Baumann A-L, Grote M, et al. TriFabs—trivalent IgG-shaped bispecific antibody derivatives: design, generation, characterization and application for targeted payload delivery. Int J Mol Sci. 2015;16(11):27497–27507.
   PubMed Web of Science ®Google Scholar
• Moore PA, Zhang W, Rainey GJ, et al. Application of dual affinity retargeting molecules to achieve optimal redirected T-cell killing of B-cell lymphoma. Blood. 2011;117(17):4542–4551.
   PubMed Web of Science ®Google Scholar
• Reusch U, Duell J, Ellwanger K, et al. A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19 + tumor cells. MAbs. 2015;7(3):584–604.
   PubMed Web of Science ®Google Scholar
• Liu L, Lam C-YK, Long V, et al. MGD011, A CD19 x CD3 dual-affinity retargeting bi-specific molecule incorporating extended circulating half-life for the treatment of B-cell malignancies. Clin Cancer Res. 2017;23(6):1506–1518.
   PubMed Web of Science ®Google Scholar
• Einsele H, Borghaei H, Orlowski RZ, et al. The BiTE (bispecific T-cell engager) platform: development and future potential of a targeted immuno-oncology therapy across tumor types. Cancer. 2020;126(14):3192–3201.
   PubMed Web of Science ®Google Scholar
• Popplewell L, Verhoef G, Kuruvilla J, et al. A first-in-human study of a half-life extended CD19-targeting BiTE in relapsed/refractory diffuse large B cell lymphoma, mantle cell lymphoma or follicular lymphoma. [Abstract]. Hematol Oncol. 2019;37(S2):566.
   Google Scholar
• Dworzak MN, Schumich A, Printz D, et al. CD20 up-regulation in pediatric B-cell precursor acute lymphoblastic leukemia during induction treatment: setting the stage for anti-CD20 directed immunotherapy. Blood. 2008;112(10):3982–3988.
   PubMed Web of Science ®Google Scholar
• Szczepanowski M, Richter J, Kehden B, et al. CD20 Expression and response to Rituximab treatment in B-cell precursor lymphoblastic leukemia - results of the GMALL 08/2013 trial. [Abstract]. Blood. 2018;132(Supplement 1):1409.
   Google Scholar
• Bannerji R, Arnason JE, Advani R, et al. Emerging clinical activity of REGN1979, an Anti-CD20 x Anti-CD3 bispecific antibody, in patients with relapsed/refractory follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), and other B-Cell non-Hodgkin lymphoma (B-NHL) subtypes. [Abstract]. Blood. 2018;132(Supplement 1):1690.
   Google Scholar
• Dickinson MJ, Morschhauser F, Iacoboni G, et al. CD20-TCB (RG6026), a Novel “2:1” format T-cell-engaging bispecific antibody, induces complete remissions in relapsed/refractory B-cell non-Hodgkin’s lymphoma. Hematol Oncol. 2019;37(S2):92–93.
   PubMedGoogle Scholar
• Kieslich A, Ruf P, Lindhofer H, et al. Immunotherapy with the trifunctional anti-CD20 × anti-CD3 antibody FBTA05 in a patient with relapsed t(8;14)-positive post-transplant lymphoproliferative disease. Leuk Lymphoma. 2017;58(8):1989–1992.
   PubMed Web of Science ®Google Scholar
• Roche announces new data on novel CD20-CD3 bispecific cancer immunotherapies in people with difficult-to-treat lymphomas, Investor Roche Update. 2019 [cited 2020 Jun 11]. https://www.roche.com/dam/jcr:054ac171-6fc7-4b73-8436-d31809849747/en/191207-ir-ash-cd20-cd3-bispecific-en.pdf
   Google Scholar
• Bacac M, Colombetti S, Herter S, et al. CD20-TCB with Obinutuzumab pretreatment as next-generation treatment of hematologic malignancies. Clin Cancer Res. 2018 [cited 2020 Jun 11];24(19):4785–4797.
   PubMed Web of Science ®Google Scholar
• Buhmann R, Michael S, Juergen H, et al. Immunotherapy with FBTA05 (Bi20), a trifunctional bispecific anti-CD3 x anti-CD20 antibody and donor lymphocyte infusion (DLI) in relapsed or refractory B-cell lymphoma after allogeneic stem cell transplantation: study protocol of an investigator-driven, open-label, non-randomized, uncontrolled, dose-escalating Phase I/II-trial. J Transl Med. 2013;11:160.
   PubMed Web of Science ®Google Scholar
• Du W, Li X-E, Sipple J, et al. Overexpression of IL-3Rα on CD34+CD38− stem cells defines leukemia-initiating cells in Fanconi anemia AML. Blood. 2011;117(16):4243–4252.
   PubMed Web of Science ®Google Scholar
• Pemmaraju N, Lane AA, Sweet KL, et al. Tagraxofusp in blastic plasmacytoid dendritic-cell neoplasm. N Engl J Med. 2019;380(17):1628–1637.
   PubMed Web of Science ®Google Scholar
• Boissel N, Botton S, Thomas X, et al. An open-label, first-in-human, dose escalation study of a novel CD3-CD123 bispecific T-cell engager administered as a single agent by intravenous infusion in patients with relapsed or refractory acute myeloid leukemia, B-cell acute lymphoblastic leukemia, or high risk myelodysplastic syndrome. J Clin Oncol. 2018;36(15_Suppl):TPS7076.
   Web of Science ®Google Scholar
• Comeau MR, Miller RE, Bader R, et al. Abstract 1786: APVO436, a bispecific anti-CD123 x anti-CD3 ADAPTIs” molecule for redirected T-cell cytotoxicity, induces potent T-cell activation, proliferation and cytotoxicity with limited cytokine release. [Abstract]. Cancer Res. 2018;78:1786.
   Web of Science ®Google Scholar
• Gaudet F, Nemeth JF, McDaid R, et al. Development of a CD123xCD3 bispecific antibody (JNJ-63709178) for the treatment of Acute myeloid leukemia (AML). [Abstract]. Blood. 2016;128(22):2824.
   PubMed Web of Science ®Google Scholar
• Uy GL, Rettig MP, Vey N, et al. Phase 1 cohort expansion of Flotetuzumab, a CD123×CD3 bispecific Dart® protein in patients with relapsed/refractory acute myeloid leukemia (AML). [Abstract]. Blood. 2018;132(Supplement 1):764.
   Google Scholar
• Ravandi F, Bashey A, Foran JM, et al. Complete responses in relapsed/refractory Acute myeloid leukemia (AML) patients on a weekly dosing schedule of XmAb14045, a CD123 x CD3 T cell-engaging bispecific antibody: initial results of a phase 1 study. [Abstract]. Blood. 2018;132(Supplement 1):763.
   Google Scholar
• Jitschin R, Saul D, Braun M, et al. CD33/CD3-bispecific T-cell engaging (BiTE®) antibody construct targets monocytic AML myeloid-derived suppressor cells. J Immunother Cancer. 2018;6(1):116.
   PubMedGoogle Scholar
• van Rhenen A, van Dongen GAMS, Kelder A, et al. The novel AML stem cell–associated antigen CLL-1 aids in discrimination between normal and leukemic stem cells. Blood. 2007;110(7):2659–2666.
   PubMed Web of Science ®Google Scholar
• Novakova M, Vakrmanova B, Slamova L, et al. PF176 monocytic switch and discrepancy between flow cytometric and molecular minimal residual disease are frequent in DUX4 rearranged and PAX5-P80R mutated B-cell precursor acute lymphoblastic leukemia. [Abstract]. HemaSphere. 2019;3(S1):40.
   Google Scholar
• Arndt C, Feldmann A, von Bonin M, et al. Costimulation improves the killing capability of T cells redirected to tumor cells expressing low levels of CD33: description of a novel modular targeting system. Leukemia. 2014;28(1):59–69.
   PubMed Web of Science ®Google Scholar
• Hoseini SS, Guo H, Wu Z, et al. A potent tetravalent T-cell–engaging bispecific antibody against CD33 in acute myeloid leukemia. Blood Advances. 2018;2(11):1250–1258.
   PubMed Web of Science ®Google Scholar
• Krupka C, Kufer P, Kischel R, et al. CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell–engaging antibody AMG 330. Blood. 2014;123(3):356–365.
   PubMed Web of Science ®Google Scholar
• Reusch U, Harrington KH, Gudgeon CJ, et al. Characterization of CD33/CD3 tetravalent bispecific tandem diabodies (TandAbs) for the treatment of Acute myeloid leukemia. Clin Cancer Res. 2016;22(23):5829–5838.
   PubMed Web of Science ®Google Scholar
• Westervelt P, Cortes JE, Altman JK, et al. Phase 1 first-in-human trial of AMV564, a bivalent bispecific (2:2) CD33/CD3 T-cell engager, in patients with relapsed/refractory Acute myeloid leukemia (AML). [Abstract]. Blood. 2019;134(Supplement_1):834.
   Google Scholar
• van Loo PF, Hangalapura BN, Thordardottir S, et al. MCLA-117, a CLEC12AxCD3 bispecific antibody targeting a leukaemic stem cell antigen, induces T cell-mediated AML blast lysis. Expert Opin Biol Ther. 2019;19(7):721–733.
   PubMed Web of Science ®Google Scholar
• Liu F, Cao Y, Pinz K, et al. First-in-human CLL1-CD33 compound CAR T cell therapy induces complete remission in patients with refractory Acute myeloid leukemia: update on phase 1 clinical trial. [Abstract]. Blood. 2018;132(Supplement 1):901.
   Google Scholar
• Dheilly E, Moine V, Broyer L, et al. Selective blockade of the ubiquitous checkpoint receptor CD47 is enabled by dual-targeting bispecific antibodies. Mol Ther. 2017;25(2):523–533.
   PubMed Web of Science ®Google Scholar
• Rothe A, Sasse S, Topp MS, et al. A phase 1 study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma. Blood. 2015;125(26):4024–4031.
   PubMed Web of Science ®Google Scholar
• Herrmann M, Krupka C, Deiser K, et al. Bifunctional PD-1 × αCD3 × αCD33 fusion protein reverses adaptive immune escape in acute myeloid leukemia. Blood. 2018;132(23):2484–2494.
   PubMed Web of Science ®Google Scholar
• Correnti CE, Laszlo GS, de van der Schueren WJ, et al. Simultaneous multiple interaction T-cell engaging (SMITE) bispecific antibodies overcome bispecific T-cell engager (BiTE) resistance via CD28 co-stimulation. Leukemia. 2018;32(5):1239–1243.
   PubMed Web of Science ®Google Scholar
• Felices M, Lenvik TR, Davis ZB, et al. Generation of BiKEs and TriKEs to improve NK cell-mediated targeting of tumor cells. Methods Mol Biol. 2016;1441:333–346.
   PubMedGoogle Scholar
• Vallera DA, Felices M, McElmurry R, et al. IL15 trispecific killer engagers (TriKE) make natural killer cells specific to CD33 + targets while also inducing persistence, in vivo expansion, and enhanced function. Clin Cancer Res. 2016;22(14):3440–3450.
   PubMed Web of Science ®Google Scholar
• Choi BD, Yu X, Castano AP, et al. CAR-T cells secreting BiTEs circumvent antigen escape without detectable toxicity. Nat Biotechnol. 2019;37(9):1049–1058.
   PubMed Web of Science ®Google Scholar
• Wing A, Fajardo CA, Posey AD Jr., et al. Improving CART-cell therapy of solid tumors with oncolytic virus–driven production of a bispecific T-cell engager. Cancer Immunol Res. 2018;6(5):605–616.
   PubMed Web of Science ®Google Scholar
• Feins S, Kong W, Williams EF, et al. An introduction to chimeric antigen receptor (CAR) T-cell immunotherapy for human cancer. Am J Hematol. 2019;94(S1):S3–S9.
   PubMed Web of Science ®Google Scholar
• June CH, O’Connor RS, Kawalekar OU, et al. CAR T cell immunotherapy for human cancer. Science. 2018;359(6382):1361–1365.
   PubMed Web of Science ®Google Scholar
• Roddie C, O’Reilly M, Dias Alves Pinto J. Manufacturing chimeric antigen receptor T cells: issues and challenges. Cytotherapy. 2019;21(3):327–340.
   PubMed Web of Science ®Google Scholar
• Goebeler ME, Bargou RC. T cell-engaging therapies - BiTEs and beyond. Nat Rev Clin Oncol. 2020;17(7):418–434.
   PubMed Web of Science ®Google Scholar
• Lee DW, Kochenderfer JN, Stetler-Stevenson M, et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet. 2015;385(9967):517–528.
   PubMed Web of Science ®Google Scholar
• Song M-K, Park -B-B, Uhm J-E. Resistance mechanisms to CAR T-cell therapy and overcoming strategy in B-cell hematologic malignancies. Int J Mol Sci. 2019;20(20):5010.
   Web of Science ®Google Scholar
• Turtle CJ, Hanafi L-A, Berger C, et al. CD19 CAR–T cells of defined CD4+:CD8+ composition in adult B cell ALL patients. J Clin Invest. 2016;126(6):2123–2138.
   PubMed Web of Science ®Google Scholar
• He X, Xiao X, Li Q, et al. Anti-CD19 CAR-T as a feasible and safe treatment against central nervous system leukemia after intrathecal chemotherapy in adults with relapsed or refractory B-ALL. Leukemia. 2019;33(8):2102–2104.
   PubMed Web of Science ®Google Scholar
• Zhang H, Hu Y, Wei G, et al. Successful chimeric antigen receptor T cells therapy in extramedullary relapses of acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplantation. 2020;55(7):1476–1478.
   PubMed Web of Science ®Google Scholar
• Shah BD, Oluwole OO, Baer MR, et al. KTE-C19, an anti-CD19 chimeric antigen receptor (CAR) T cell therapy, in adult patients with relapsed/refractory Acute lymphoblastic leukemia (R/R ALL): outcomes in patients who were treated with prior Blinatumomab in ZUMA-3. Clinical Lymphoma Myeloma and Leukemia. 2018;18:S184.
   Web of Science ®Google Scholar
• Delea TE, Amdahl J, Boyko D, et al. Cost-effectiveness of blinatumomab versus salvage chemotherapy in relapsed or refractory philadelphia-chromosome-negative B-precursor acute lymphoblastic leukemia from a US payer perspective. Journal of Medical Economics. 2017;20(9):911–922.
   PubMed Web of Science ®Google Scholar
• Delea TE, Zhang X, Amdahl J, et al. Cost effectiveness of Blinatumomab versus Inotuzumab Ozogamicin in adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia in the United States. Pharmacoeconomics. 2019;37(9):1177–1193.
   PubMed Web of Science ®Google Scholar
• Critchlow S, Cooper M, van Oostrum I, et al. Estimating the relative treatment effect and corresponding cost-effectiveness estimates of Inotuzumab Ozogamicin Vs. Blinatumomab for adults with philadelphia chromosome-negative (Ph-) relapsed/refractory (R/R) B-cell acute lymphoblastic leukaemia (B-ALL) in the United Kingdom (UK). [Abstract]. Blood. 2019;134(Supplement_1):3427.
   Google Scholar